<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0003003'>Colon cancer</z:hpo> is one of the most commonly diagnosed <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> in the United States </plain></SENT>
<SENT sid="1" pm="."><plain>Recombinant <z:chebi fb="14" ids="32506">MDA</z:chebi>-7/IL-24 has showed its selective cytotoxicity against <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells, and Ad-mda7 (INGN-241) is currently under clinical investigation for <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we investigated the expression of <z:chebi fb="14" ids="32506">MDA</z:chebi>-7/IL-24 in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) tissues from 202 patients </plain></SENT>
<SENT sid="3" pm="."><plain>Compared with the adjacent mucosa, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> tissues displayed significantly lower <z:chebi fb="14" ids="32506">MDA</z:chebi>-7/IL-24 levels </plain></SENT>
<SENT sid="4" pm="."><plain>The <z:chebi fb="14" ids="32506">MDA</z:chebi>-7/IL-24 levels in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> were significantly associated with patients' survival rate in a 6-year period </plain></SENT>
<SENT sid="5" pm="."><plain>These results indicate <z:chebi fb="14" ids="32506">MDA</z:chebi>-7/IL-24 level is both a diagnostic and prognostic biomarker for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, and support the role of <z:chebi fb="14" ids="32506">MDA</z:chebi>-7/IL-24 in the treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>To elevate <z:chebi fb="14" ids="32506">MDA</z:chebi>-7/IL-24 level for <z:hpo ids='HP_0003003'>colon cancer</z:hpo> treatment, we successfully developed a small-molecule compound SC144 with the ability to up-regulate <z:chebi fb="14" ids="32506">MDA</z:chebi>-7/IL-24 expression via direct binding to and stabilizing <z:chebi fb="14" ids="32506">MDA</z:chebi>-7/IL-24 in human <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cells </plain></SENT>
<SENT sid="7" pm="."><plain>Among the analogs tested, SC144 exhibited the highest cytotoxicity in a panel of <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cell lines in a p53-independent manner, accompanied by cell cycle arrest in G0/G1 with downregulation of Cyclin D1 levels, and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> induction with upregulation of cell surface-bound Fas/CD95 </plain></SENT>
<SENT sid="8" pm="."><plain>These results combined with our previous studies support the anticancer role of <z:chebi fb="14" ids="32506">MDA</z:chebi>-7/IL-24 as well as the clinical development of SC144 for <z:hpo ids='HP_0003003'>colon cancer</z:hpo> treatment </plain></SENT>
</text></document>